Suomi - suomi - Fimea (Suomen lääkevirasto)

orion corporation - budesonide, formoterol fumarate dihydrate - inhalaatiojauhe - 80 mikrog / 4,5 mikrog / inhalaatio - formoteroli ja budesonidi

Euroopan unioni - suomi - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - obstruktiivisten hengitystiesairauksien lääkkeet, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

Euroopan unioni - suomi - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - obstruktiivisten hengitystiesairauksien lääkkeet, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

Suomi - suomi - Fimea (Suomen lääkevirasto)

astrazeneca oy - budesonide, formoterol fumarate dihydrate - inhalaatiosumute, suspensio - 80 mikrog / 2.25 mikrog / inhalaatio - formoteroli ja budesonidi

Euroopan unioni - suomi - EMA (European Medicines Agency)

stada arzneimittel ag - budesonide, micronised - glomerulonephritis, iga - ripulilääkkeet, suoliston antiinflammatory / antiinfective agents - kinpeygo is indicated for the treatment of primary immunoglobulin a (iga) nephropathy (igan) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (upcr) ≥1. 5 g/gram.

Suomi - suomi - Fimea (Suomen lääkevirasto)

orion corporation - budesonide, formoterol fumarate dihydrate - inhalaatiojauhe - 160 mikrog / 4,5 mikrog / inhalaatio - formoteroli ja budesonidi

Euroopan unioni - suomi - EMA (European Medicines Agency)

dr. falk pharma gmbh - budesonide - ruokatorven taudit - ripulilääkkeet, suoliston antiinflammatory / antiinfective agents - jorveza on tarkoitettu kohtelu eosinofiilinen ruokatorvitulehdus (eoe) aikuiset (yli 18 vuotta).

Euroopan unioni - suomi - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - keuhkosairaus, krooninen obstruktiivinen - obstruktiivisten hengitystiesairauksien lääkkeet, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

Suomi - suomi - Fimea (Suomen lääkevirasto)

mylan ab - budesonidum - nenäsumute, suspensio - 50 mikrog/annos - budesonidi

Suomi - suomi - Fimea (Suomen lääkevirasto)

mylan ab - budesonidum - nenäsumute, suspensio - 100 mikrog/annos - budesonidi